Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill

Critical Care Clinics

Volumn 35, Issue 2, 2019, Pages 213-227

  Bitker, Laurent ^a   Burrell, Louise M ^b  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute kidney injury; Acute respiratory distress syndrome; Angiotensin; Angiotensin converting enzyme; Inflammation; Renin; Sepsis; Septic shock

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN III; ANGIOTENSINOGEN; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; G PROTEIN COUPLED RECEPTOR; MAS RECEPTOR; RENIN; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); PEPTIDE FRAGMENT; VASOCONSTRICTOR AGENT;

ACID BASE BALANCE; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; AUTOCRINE EFFECT; CRITICALLY ILL PATIENT; ENZYME INHIBITION; FIBROGENESIS; GLOMERULUS FILTRATION RATE; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; KIDNEY BLOOD FLOW; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEPTIC SHOCK; SHOCK; SODIUM HOMEOSTASIS; UPREGULATION; VASOPLEGIA; VASOPLEGIC SHOCK; ADULT; AGED; BLOOD PRESSURE; CRITICAL ILLNESS; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN I; ANGIOTENSIN II; BLOOD PRESSURE; CRITICAL ILLNESS; FEMALE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RENIN-ANGIOTENSIN SYSTEM; RESPIRATORY DISTRESS SYNDROME, ADULT; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 85060511960     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2018.11.002     Document Type: Review

References (94)

1. Doerschug, K.C., Delsing, A.S., Schmidt, G.A., et al. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care, 14(1), 2010, R24.
2. Khanna, A., English, S.W., Wang, X.S., et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377:5 (2017), 419–430.
3. Khan, A., Benthin, C., Zeno, B., et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care, 21(1), 2017, 234.
4. Cruces, P., Diaz, F., Puga, A., et al. Angiotensin-converting enzyme insertion/deletion polymorphism is associated with severe hypoxemia in pediatric ARDS. Intensive Care Med 38:1 (2012), 113–119.
5. Annoni, F., Orbegozo Cortés, D., Irazabal, M., et al. Angiotensin converting enzymes in patients with acute respiratory distress syndrome. Intensive Care Med Exp, 3(1), 2015, A91.
6. Zhang, W., Chen, X., Huang, L., et al. Severe sepsis: low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med 7:5 (2014), 1342–1348.
7. Tumlin, J.A., Murugan, R., Deane, A.M., et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med 46:6 (2018), 949–957.
8. Sparks, M.A., Crowley, S.D., Gurley, S.B., et al. Classical renin-angiotensin system in kidney physiology. Compr Physiol 4:3 (2014), 1201–1228.
9. Ballermann, B.J., Onuigbo, M.A., Angiotensins. Compr Physiol(Supplement 22), 2011, 104–155.
10. Chappell, M.C., Nonclassical renin-angiotensin system and renal function. Compr Physiol 2:4 (2012), 2733–2752.
11. Paul, M., Poyan Mehr, A., Kreutz, R., Physiology of local renin-angiotensin systems. Physiol Rev 86:3 (2006), 747–803.
12. Yang, T., Xu, C., Physiology and pathophysiology of the intrarenal renin-angiotensin system: an update. J Am Soc Nephrol 28:4 (2017), 1040–1049.
13. Matsusaka, T., Niimura, F., Shimizu, A., et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol 23:7 (2012), 1181–1189.
14. Wright, J.W., Bechtholt, A.J., Chambers, S.L., et al. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Peptides 17:8 (1996), 1365–1371.
15. Kramar, E.A., Harding, J.W., Wright, J.W., Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 68:2 (1997), 131–138.
16. Handa, R.K., Krebs, L.T., Harding, J.W., et al. Angiotensin IV AT4-receptor system in the rat kidney. Am J Physiol 274:2 Pt 2 (1998), F290–F299.
17. Bock, H.A., Hermle, M., Brunner, F.P., et al. Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 41:2 (1992), 275–280.
18. Thurau, K., Schnermann, J., Nagel, W., et al. Composition of tubular fluid in the macula densa segment as a factor regulating the function of the juxtaglomerular apparatus. Circ Res 21:1 Suppl 2 (1967), 79–90.
19. Kirchheim, H.R., Ehmke, H., Hackenthal, E., et al. Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs. Pflugers Arch 410:4–5 (1987), 441–449.
20. Rohrwasser, A., Morgan, T., Dillon, H.F., et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension 34:6 (1999), 1265–1274.
21. Mackins, C.J., Kano, S., Seyedi, N., et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest 116:4 (2006), 1063–1070.
22. Hornig, B., Kohler, C., Drexler, H., Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95:5 (1997), 1115–1118.
23. Alhenc-Gelas, F., Corvol, P., Molecular and physiological aspects of angiotensin I converting enzyme. Compr Physiol(Supplement 22), 2011, 81–103.
24. Bruneval, P., Hinglais, N., Alhenc-Gelas, F., et al. Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization. Histochemistry 85:1 (1986), 73–80.
25. Coppo, M., Bandinelli, M., Chiostri, M., et al. Persistent and selective upregulation of renin-angiotensin system in circulating T lymphocytes in unstable angina. J Renin Angiotensin Aldosterone Syst, 18(1), 2017 1470320317698849.
26. Guthrie, G.P. Jr., Angiotensin receptors: physiology and pharmacology. Clin Cardiol, 18(6 Suppl 3), 1995 III 29–34.
27. Allen, A.M., Zhuo, J., Mendelsohn, F.A., Localization and function of angiotensin AT1 receptors. Am J Hypertens 13:1 Pt 2 (2000), 31S–38S.
28. Hernandez-Presa, M., Bustos, C., Ortego, M., et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:6 (1997), 1532–1541.
29. Zhang, J.D., Patel, M.B., Song, Y.S., et al. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 110:12 (2012), 1604–1617.
30. Taal, M.W.B., Barry, M., 1937-; Rector. Floyd, C., (eds.) Brenner & Rector's the kidney, 9th edition, 2012, Elsevier/Saunders, Philadelphia.
31. Hall, J.E., Guyton, A.C., Cowley, A.W. Jr., Dissociation of renal blood flow and filtration rate autoregulation by renin depletion. Am J Physiol 232:3 (1977), F215–F221.
32. Geibel, J., Giebisch, G., Boron, W.F., Angiotensin II stimulates both Na(+)-H+ exchange and Na+/HCO3− cotransport in the rabbit proximal tubule. Proc Natl Acad Sci U S A 87:20 (1990), 7917–7920.
33. Wall, S.M., Lazo-Fernandez, Y., The role of pendrin in renal physiology. Annu Rev Physiol 77 (2015), 363–378.
34. Hall, J.E., Guyton, A.C., Smith, M.J. Jr., et al. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. Am J Physiol 239:3 (1980), F271–F280.
35. Heinemann, A., Wachter, C.H., Holzer, P., et al. Nitric oxide-dependent and -independent vascular hyporeactivity in mesenteric arteries of portal hypertensive rats. Br J Pharmacol 121:5 (1997), 1031–1037.
36. Myers, B.D., Deen, W.M., Brenner, B.M., Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 37:1 (1975), 101–110.
37. Suvannapura, A., Levens, N.R., Local control of mesenteric blood flow by the renin-angiotensin system. Am J Physiol 255:3 Pt 1 (1988), G267–G274.
38. Rossi, G.P., Sacchetto, A., Cesari, M., et al. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 43:2 (1999), 300–307.
39. Peach, M.J., Adrenal medullary stimulation induced by angiotensin I, angiotensin II, and analogues. Circ Res 28:5 Suppl 2 (1971), 107–117.
40. Cingolani, H.E., Villa-Abrille, M.C., Cornelli, M., et al. The positive inotropic effect of angiotensin II: role of endothelin-1 and reactive oxygen species. Hypertension 47:4 (2006), 727–734.
41. Coble, J.P., Grobe, J.L., Johnson, A.K., et al. Mechanisms of brain renin angiotensin system-induced drinking and blood pressure: importance of the subfornical organ. Am J Physiol Regul Integr Comp Physiol 308:4 (2015), R238–R249.
42. Dendorfer, A., Thornagel, A., Raasch, W., et al. Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension 40:3 (2002), 348–354.
43. Santos, R.A., Simoes e Silva, A.C., Maric, C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100:14 (2003), 8258–8263.
44. Flores-Munoz, M., Smith, N.J., Haggerty, C., et al. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol 589:Pt 4 (2011), 939–951.
45. Fattah, C., Nather, K., McCarroll, C.S., et al. Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction. J Am Coll Cardiol 68:24 (2016), 2652–2666.
46. Donoghue, M., Hsieh, F., Baronas, E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:5 (2000), E1–E9.
47. Tipnis, S.R., Hooper, N.M., Hyde, R., et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:43 (2000), 33238–33243.
48. Chappell, M.C., Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 50:4 (2007), 596–599.
49. Wiener, R.S., Cao, Y.X., Hinds, A., et al. Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. J Cell Biochem 101:5 (2007), 1278–1291.
50. Towler, P., Staker, B., Prasad, S.G., et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 279:17 (2004), 17996–18007.
51. Gwathmey, T.M., Westwood, B.M., Pirro, N.T., et al. Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide. Am J Physiol Renal Physiol 299:5 (2010), F983–F990.
52. Qi, Y., Shenoy, V., Wong, F., et al. Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol 96:9 (2011), 863–874.
53. Grobe, J.L., Der Sarkissian, S., Stewart, J.M., et al. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) 113:8 (2007), 357–364.
54. Burrell, L.M., Risvanis, J., Kubota, E., et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26:4 (2005), 369–375 [discussion: 322–64].
55. Trask, A.J., Groban, L., Westwood, B.M., et al. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens 23:6 (2010), 687–693.
56. Tallant, E.A., Ferrario, C.M., Gallagher, P.E., Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289:4 (2005), H1560–H1566.
57. Patel, V.B., Bodiga, S., Fan, D., et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension 59:6 (2012), 1195–1203.
58. Velkoska, E., Dean, R.G., Griggs, K., et al. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) 120:8 (2011), 335–345.
59. Heller, J., Kramer, H.J., Maly, J., et al. Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney Blood Press Res 23:2 (2000), 89–94.
60. Pinheiro, S.V., Ferreira, A.J., Kitten, G.T., et al. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75:11 (2009), 1184–1193.
61. Zhang, J., Noble, N.A., Border, W.A., et al. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298:3 (2010), F579–F588.
62. Jin, H.Y., Chen, L.J., Zhang, Z.Z., et al. Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling. J Transl Med, 13, 2015, 255.
63. Oudit, G.Y., Liu, G.C., Zhong, J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:2 (2010), 529–538.
64. Lely, A.T., Hamming, I., van Goor, H., et al. Renal ACE2 expression in human kidney disease. J Pathol 204:5 (2004), 587–593.
65. Reich, H.N., Oudit, G.Y., Penninger, J.M., et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 74:12 (2008), 1610–1616.
66. Bernstein, K.E., Khan, Z., Giani, J.F., et al. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol 14:5 (2018), 325–336.
67. Sachse, A., Wolf, G., Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18:9 (2007), 2439–2446.
68. Khan, Z., Shen, X.Z., Bernstein, E.A., et al. Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils. Blood 130:3 (2017), 328–339.
69. Okwan-Duodu, D., Datta, V., Shen, X.Z., et al. Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus. J Biol Chem 285:50 (2010), 39051–39060.
70. Meng, Y., Chen, C., Liu, Y., et al. Angiotensin II regulates dendritic cells through activation of NF-kappaB/p65, ERK1/2 and STAT1 pathways. Cell Physiol Biochem 42:4 (2017), 1550–1558.
71. Abraham, E., Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 187:Suppl 2 (2003), S364–S369.
72. Ozawa, Y., Kobori, H., Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury. Am J Physiol Renal Physiol 293:1 (2007), F100–F109.
73. Shen, X.Z., Li, P., Weiss, D., et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol 170:6 (2007), 2122–2134.
74. Zambelli, V., Bellani, G., Borsa, R., et al. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. Intensive Care Med Exp, 3(1), 2015, 44.
75. Hilgenfeldt, U., Kienapfel, G., Kellermann, W., et al. Renin-angiotensin system in sepsis. Clin Exp Hypertens A 9:8–9 (1987), 1493–1504.
76. Casey, L., Krieger, B., Kohler, J., et al. Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report. Crit Care Med 9:9 (1981), 651–654.
77. Shen, L., Mo, H., Cai, L., et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 31:5 (2009), 500–506.
78. Graninger, M., Marsik, C., Dukic, T., et al. Enalapril does not alter adhesion molecule levels in human endotoxemia. Shock 19:5 (2003), 448–451.
79. Dial, S., Nessim, S.J., Kezouh, A., et al. Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. Br J Clin Pharmacol 78:5 (2014), 1151–1158.
80. Rodgers, K., Xiong, S., Espinoza, T., et al. Angiotensin II increases host resistance to peritonitis. Clin Diagn Lab Immunol 7:4 (2000), 635–640.
81. Reddy, L.M., Baydur, L., Liebler, J.M., et al. The role of renin-angiotensin peptides in the pathogenesis of acute respiratory distress syndrome. Am J Respir Crit Care Med, 195, 2017, A4773.
82. Wosten-van Asperen, R.M., Lutter, R., Specht, P.A., et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol 225:4 (2011), 618–627.
83. Raiden, S., Nahmod, K., Nahmod, V., et al. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J Pharmacol Exp Ther 303:1 (2002), 45–51.
84. Wosten-van Asperen, R.M., Lutter, R., Specht, P.A., et al. Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme. Am J Pathol 176:5 (2010), 2219–2227.
85. Kuba, K., Imai, Y., Rao, S., et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11:8 (2005), 875–879.
86. Imai, Y., Kuba, K., Rao, S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436:7047 (2005), 112–116.
87. Treml, B., Neu, N., Kleinsasser, A., et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med 38:2 (2010), 596–601.
88. Haschke, M., Schuster, M., Poglitsch, M., et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52:9 (2013), 783–792.
89. Cao, W., Jin, L., Zhou, Z., et al. Overexpression of intrarenal renin-angiotensin system in human acute tubular necrosis. Kidney Blood Press Res 41:6 (2016), 746–756.
90. Alge, J.L., Karakala, N., Neely, B.A., et al. Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol 8:2 (2013), 184–193.
91. Lankadeva, Y.R., Kosaka, J., Evans, R.G., et al. Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury. Crit Care Med 46:1 (2018), e41–e48.
92. Efrati, S., Berman, S., Hamad, R.A., et al. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. Nephrol Dial Transplant 27:1 (2012), 136–145.
93. Zhang, J., Rudemiller, N.P., Patel, M.B., et al. Competing actions of type 1 angiotensin II receptors expressed on T lymphocytes and kidney epithelium during cisplatin-induced AKI. J Am Soc Nephrol 27:8 (2016), 2257–2264.
94. Fang, F., Liu, G.C., Zhou, X., et al. Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. PLoS One, 8(8), 2013, e71433.